Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

Dr Suchitra Sundaram describes critical disparities in DLBCL treatment, urging for equitable access to care and representation in clinical trials.

Dr Matthew McKinney reflects on his first experience of treating DLBCL and highlights the advancements in emerging treatments ...

Caregiving can take many forms, often requiring a profound shift in daily life. While navigating a disease is an immense ...

AstraZeneca's Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreate ...

AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...

The new first-line MCL indication gives Calquence a slice of the market of its own and could spur further growth of the drug, ...

During a Case-Based Roundtable® event, Jean A. Yared, MD, moderated a discussion on the approach to CAR T-cell therapy for a ...

The following is a summary of “Limited Benefit of Routine Clinical Follow-Up for Relapse Detection in Diffuse Large B-Cell ...

NEW YORK — Roche said on Monday that it has received clearance from the US Food and Drug Administration for an in situ hybridization test to assess the full spectrum of B-cell lymphoma subtypes.

B-cell lymphoma accounts for approximately 85 percent of non-Hodgkin ... an infection is critical in ensuring accurate and timely diagnosis, especially as the symptoms can appear similar," said Jill ...